NCT06732960

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients

A Randomized, Double-Blind, Placebo-controlled Study of Efsubaglutide Alfa on Weight Management in Subjects With Overweight or Obesity to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa at difference dose range once-weekly in patients with Overweight or Obesity.

Detailed description

This study will look at the adverse events and the change in participants' body weight from the start of the study to the end. Weight loss in participants taking Efsubaglutide Alfa will be compared to weight loss in participants taking placebo.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
BIOLOGICAL	Efsubaglutide Alfa	Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.
OTHER	Placebo	Placebo subcutaneous injection weekly

Timeline

• Start date: 2024-04-21
• Primary completion: 2024-11-18
• Completion: 2024-11-18
• First posted: 2024-12-13
• Last updated: 2025-04-02

Locations

3 sites across 1 country: China